In April of last year, the US Food and Drug Administration invited three large biotech companies – Geron, Advanced Cell Technology, and Novocell – to testify about how to safely test human embryonic stem cell (ESC) products in patients. The science was discussed, recommendations were made, and, seemingly, everyone was on the same page toward moving ESCs into the clinic.
Office of Strategic Communication